Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

2.1 Tepotinib (Tepmetko, Merck) is indicated for 'the treatment of adult patients with advanced non-small-cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations'.

2.2 The dosage schedule is available in the summary of product characteristics for tepotinib.

2.3 The list price of tepotinib is £7,200 for 60×250‑mg tablets. The company has a commercial arrangement. This makes tepotinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.